Sungwon
Lim

Most cancer treatment begins with an educated guess. A doctor picks a drug based on statistics, protocols, and experience - then watches to see if it works. For many patients, weeks pass before it becomes clear the choice was wrong. Those weeks are irreplaceable.

Dr. Sungwon Lim decided the guess was the problem. His company, ImpriMed, takes a sample of a patient's actual, live cancer cells - then tests them against a panel of 13 drugs in real time. The AI analyzes which ones trigger cell death, generates a personalized treatment prediction report, and delivers it to the oncologist within seven days. Before the first dose is prescribed.

The results are not theoretical. Dogs with relapsed B-cell lymphoma that received treatment matching ImpriMed's AI predictions saw median survival extended to 160-187 days. In clinical terms, the AI tripled survival rates and quadrupled response rates compared to unmatched treatment. Ninety-five percent of the 87 veterinary oncologists surveyed said they were satisfied with the reports.

Yes, dogs. That part is deliberate - and it was a stroke of strategic brilliance that turned a regulatory wall into a launchpad.

That quote - delivered by his mentor at a pivotal moment in his academic career - is the compass Lim has navigated by ever since. He was already reconsidering a trajectory toward computer programming when he encountered it. The sentence reoriented everything: away from software, toward bioengineering. Away from products for the few, toward technologies that scale.

He did his PhD in Bioengineering at Stanford. He met his co-founder Jamin Koo as an undergraduate; both would eventually hold PhDs from Stanford and KAIST. They incorporated ImpriMed in 2017, the same year Lim finished his doctorate, driven by a shared conviction that cancer treatment was still too much art, not enough science.

Sungwon Lim was eight years old when his grandfather died of cancer. It's the kind of early loss that either leaves a quiet mark or reshapes a life. For Lim, it did the latter - though not immediately.

In college, he was headed toward software. Programming made sense: it was powerful, scalable, intellectually satisfying. Then he read something - a book about long-term company values - that made him stop and inventory what he actually cared about. Two things came back: helping as many people as possible, and building foundational technologies that others could build upon.

Software could do both. But bioengineering could do both with the specific urgency of disease. He pivoted to science.

At Stanford, he pursued a PhD in Bioengineering, researching protein therapeutics, drug delivery systems, and the mechanics of how to get treatments to the cells that need them. He also met Jamin Koo - the person who would become his CTO and co-founder - and found someone who shared both the scientific rigor and the entrepreneurial impatience.

They incorporated ImpriMed in 2017, the year Lim's doctorate was complete. They spent four years in research mode before commercializing the first services in 2021. That patience - the willingness to spend years validating before monetizing - is a thread that runs through everything Lim does.